Specific Learning Objectives

• Describe the basics of the immune system’s involvement in tumour control.

• Recognize the constellation of signs and symptoms for which immune-related adverse events (irAE) should be considered in the differential diagnosis.

• Explain the work up of suspected irAEs of the endocrine system, skin, GI tract, lung and liver.

• Describe those circumstances in which the primary care clinician should initiate urgent communication with the medical oncologist of a patient who is being or has been treated with an immune checkpoint inhibitor.
Disclosure of Conflicts

- Relationships with commercial interests:
  - Grants/Research Support: NONE
  - Speakers Bureau/Honoraria: NONE
  - Consulting Fees: NONE
  - Other: NONE
- No financial incentives
- No pharmaceutical affiliation
- Medical Consultant with Canadian Virtual Hospice
- Pictures may be subject to copyright
- No off-label pharmaceutical suggestions will be made

**Special Credit**

**IMMUNOTHERAPY & its complications**

A module of the Early Cancer Diagnosis Workshop Series

An Early Diagnosis Workshop by: CancerCare Manitoba
Growth in Potential Cancer Treatments

- Surgery
- Radiation
- Hormone Therapy
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Stem Cell Transplantation
- Precision Medicine

Case 1 - Mr. G

- 2012 - 58 yr old man with 1.5 cm mobile preauricular nodule, biopsy positive for malignant melanoma
- Metastatic workup normal apart from subarachnoid cyst
- Nodule became smaller, and he was lost to follow up

- 2013 – repeat staging – negative
- “Spontaneously Regressed Intraparotid Malignant Melanoma”
Case 1 – Mr. G

• March 2014 – wide excision, superficial parotidectomy, neck dissection
• Scar, suggestive of regressed melanoma
• Unremarkable parotid tissue
• Multiple compound melanocytic nevi
• 42 nodes – all negative for melanoma

Case 1 – Mr. G

• March 2017 – laparotomy for a small bowel obstruction, suspected tumour
• Pathology positive for malignant melanoma

• July 2017 – new hepatic lesions

• August 2017
• Stage IV BRAF mutated metastatic melanoma with liver metastases
• Rx: Dabrafenib 150 mg po BID and Trametinib 2 mg po daily
• Tolerated well; October scans showed improvement
Case 1 – Mr. G

• April 2018 – routine CT shows deterioration in abdomen with development of multiple large centrally necrotic intraabdominal nodes, up to 4.5 cm diameter

Case 1 – Mr. G

• May 2018 – Pembrolizumab IV q3weeks
Immune System and Cancer Control

- The immune system has the greatest potential for the specific destruction of tumours with no toxicity to normal tissue and for long-term memory that can prevent cancer recurrence.
- Immunosurveillance depends on the recognition of tumour antigens.
- Malignant progression is accompanied by profound immune suppression that interferes with an effective antitumour response and tumour elimination.


Innate and Adaptive Immunity
Non-specific Immunotherapy

- Uses cytokines, growth factors and other substances to give the immune system a boost to fight cancer
- Cytokines trigger the immune system to fight bacteria, viruses, and disease
- Cytokines can also be made in the lab and used to treat cancer

- **Interferon alfa** - melanoma
- **Interleukin-2** - kidney cancer and melanoma
- **Bacillus Calmette-Guerin (BCG)** - early-stage bladder cancer
Phase I - PRIMING

DENDRITIC CELL

T-CELL

CANCER CELL

T-CELL

Phase II - EFFECTOR

CD 28 ACTIVATES

MAJOR HISTOCOMPATIBILITY COMPLEX

T-CELL RECEPTOR
Phase I - PRIMING

DENDRITIC CELL

CD 28 ACTIVATES

CTLA-4 INHIBITS

MAJOR HISTOCOMPATIBILITY COMPLEX

T-CELL RECEPTOR

DENDRITIC CELL

CD 28 ACTIVATES

CTLA-4 INHIBITS

ANTIBODIES

MAJOR HISTOCOMPATIBILITY COMPLEX

T-CELL RECEPTOR
Phase II - EFFECTOR

T-CELL

PD-1

PDL-1

CANCER CELL

T-CELL RECEPTOR

MAJOR HISTOCOMPATABILITY COMPLEX

Phase II - EFFECTOR

T-CELL

PD-1

PDL-1

CANCER CELL

T-CELL RECEPTOR

MAJOR HISTOCOMPATABILITY COMPLEX
**Phase II - EFFECTOR**

- **T-CELL**
- **ANTIBODIES**
  - **PD-1**
  - **PDL-1**
- **T-CELL RECEPTOR**
- **MAJOR HISTOCOMPATABILITY COMPLEX**

**CANCER CELL**

**Immunology Wars**

https://www.youtube.com/watch?v=5AXApBbj1ps
Case 2: Mrs. T

- Diagnosed with metastatic melanoma six weeks ago.
- Four weeks ago, started on a combination of nivolumab (a PD-1 inhibitor) and ipilimumab (a CTLA-4 inhibitor)
- Presents to your office complaining of an itchy, bumpy and red rash of the neck, anterior chest and upper back that started about a week ago
- In the past two days she has noticed the emergence of increasingly itchy, similar lesions more diffusely across the chest, back, waist and extremities
- Some difficulty sleeping and concentrating at work.
- No history of allergies; no exposures to similar rashes

Dermatitis and Immune Checkpoint Inhibitors

Large variety, from minor to serious

From itch, without rash, to life-threatening
Dermatologic Immune-Related Adverse Events

- inflammatory reactions such as morbilliform rash

- Psoraisiform rashes
Dermatologic Immune-Related Adverse Events

• Lichenoid reactions

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 (New Zealand at https://creativecommons.org/licenses/by-nc-nd/3.0/nz/legalcode

Dermatologic Immune-Related Adverse Events

• Immunobullous lesions resembling dermatitis herpetiformis or bullous pemphigoid

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 (New Zealand at https://creativecommons.org/licenses/by-nc-nd/3.0/nz/legalcode
Dermatologic Immune-Related Adverse Events

• Acantholytic dyskeratosis

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 (New Zealand at https://creativecommons.org/licenses/by-nc-nd/3.0/nz/legalcode

Dermatologic Immune-Related Adverse Events

• Immunologic attack on melanocytes (halo nevi, regression of nevi, tumoural melanosis and vitiligo)

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 (New Zealand at https://creativecommons.org/licenses/by-nc-nd/3.0/nz/legalcode
Case 2: Mrs. T (continued)

- On examination, the majority of her skin is affected by an erythematous maculopapular morbilliform rash.
- Heaviest on the upper chest, upper back, waist and proximal extremities, less on abdomen and distal extremities.
- You estimate it covers 70 – 80% of her skin surface.
- No pustules.
- No lip or tongue swelling.
- No vesicles or bullae.
- Oral mucosa and conjunctiva look normal.
- No lesions of the palms or soles.

Grading Dermatological Toxicity

**Case 2: Mrs. T (Management)**

- Grade 2-3 dermatitis
- Contact her oncologist / treatment team
- Hold treatment with “ipi-nivo”
- Consider urgent dermatology consult / biopsy
- Consider steroids – e.g. Prednisone 1 mg/kg/day
- Work out a plan in collaboration with the consultants for the reassessment of the patient and monitoring for response to therapy
- Steroid tapering needs to be individualized, is usually very slow, and should be done in close consultation with the involved specialists.

---

**Timing of occurrence of immune-related adverse events following ipilimumab treatment**

Time to onset of Grade 3-4 treatment-related selected adverse events


Grading Gastrointestinal Toxicity

Case 3: Ms. B

- Presents with diffuse, crampy abdominal pain in association with increasingly frequent passage of loose-to-watery stools.
- Diagnosed with a Stage IV melanoma twelve weeks ago
- PET/CT showed a lung lesion
- Began treatment 8 weeks ago with pembrolizumab
- Five weeks ago (three weeks into treatment) she was seen at a walk-in clinic complaining of diffuse itching, and was prescribed hydroxyzine 10 mg TID and hydrocortisone 1% cream, with partial benefit. At that visit she was also prescribed cloxacillin for a paronychia.
- Seven weeks into her course of therapy, she noticed an increase in the frequency of her stools, which became loose and watery 3 days ago.

What’s in the Differential Diagnosis?

- Immunotherapy toxicity
- Clostridium difficile
- Intercurrent illness
What specifics might you look for on physical exam?

• Mouth ulcers
• Anal lesions such as fistulas, abscesses and fissures
• Tenderness in the epigastrium could suggest immune-related pancreatitis
• Inflammatory changes in the bowel might be confined to the sigmoid and rectum or be distributed in a patchy fashion throughout the lower GI tract.

Case 3: Ms. B (continued)

• Ms. B looks generally well
• HR 92, RR 14, T 36.3, BP 122/78 and SPO2(RA) 96%
• Normal gingiva and normal buccal mucosa
• Lungs are clear to auscultation; heart sounds normal
• Abdomen has moderately increased bowel sounds, mild tenderness in the suprapubic area and the left lower quadrant, but no masses or organomegaly
• Skin exam is unremarkable.
Case 3: Ms. B (Management)

- Grade 2 diarrhea
- Contact her oncologist / treatment team
- Hold treatment with pembrolizumab
- Stool for cultures and C. difficile toxin
- If worsens, may require more immunologic testing, consult with gastroenterologist, urgent colonoscopy and biopsies
- Prednisone 1 mg/kg may be advised
  - NOTE: SLOW TAPER
- FOLLOW UP
The Spectrum of Immune-Related Adverse Events Related to Immune Checkpoint Inhibitors

“All the side effects Are these drugs worth it?”

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial.

- 418 patients enrolled January 2013 - February 2014
- 18 years or older with confirmed unresectable previously untreated stage III or IV melanoma ECOG perf status 0/1
- Randomized to nivolumab or dacarbazine

- 3-year overall survival: were 51.2%(N) vs 21.6%(D)
- Median survival: 37.5 months(N) vs 11.2 months(D)
- Survival in the nivolumab group ranged from 25.5 months to still alive at the end of the 3-year study
- Complete response: 19%(N) vs 1.4%(D)
- Partial response: 23.8%(N) vs 13.0%(D)
- Treatment related grade 3/4 adverse events: 15%(N) vs 17.6%(D)
- No deaths due to study drug toxic events
Case 1 – Mr. G

- May 2018 – Pembrolizumab IV q3weeks

- January 2019 – No evidence of metastatic disease!

Stay tuned for more T-cell stimulation!
Summary

1. The immune system is inherently involved in cancer control
2. Specific agents block naturally occurring immune checkpoints, increasing immune effects
3. Immune system stimulation causes a potential excessive immune response that can affect a number of systems
4. Immune side effects may be mild or serious
5. Early recognition, and early intervention are key components to effective management of immune effects
6. Ask for help earlier rather than later

Resources / Further Reading


